melanoma-2017-posters-accepted-abstracts

3 / 15

Notes:
Volume 2, Issue 3 2017 Journal of Medical Oncology and Therapeutics Dermatologists & Melanoma 2017
August 31-September 01, 2017
Page 72
&
2nd Euro-Global Congress on
August 31-September 01, 2017 London, UK
12th Global Dermatologists Congress
Melanoma and Skin Diseases
Hsin-Yu Chou et al., J Med Oncl Ther 2017, 2:3
Astaxanthin reduces MMPs to suppress melanoma proliferation and trigger fiborblasts collagen
production in vitro and in vivo
Hsin-Yu Chou1,2 and Hui-MinWang2,3,2
1National Chung Hsing University, ROC
2Kaohsiung Medical University, ROC
3Quanzhou Normal University, China
5China Medical University, ROC
The objective of this study was to assess astaxanthin as an anticancer agent to resist melanoma cells (A375 and A2058).
Melanoma was reduced in cellular migration via wound healing and invasion assay to show a dose-dependent manner
when treated with astaxanthin. Also could reduce melanoma cells migration by inhibition of MMP-1, -2 and -9 expressions. In
addition, DCFDA assay showed that the cellular ROS production was reduced. The cellular proliferation assay also showed a
dose-dependent manner to present a high inhibition. One-dimensional flow cytometric analysis demonstrated that astaxanthin
stimulated a cell cycle arrest at the G1 phase. Measurements via a double fluorescence stained image of annexin V-fluorescein
isothiocyanate (FITC)/propidium iodide (PI) to verify the apoptotic cell death mechanism. Antitumor efficacy of astaxanthin
declined tumor size significantly in xenograft model. The results indicate that astaxanthin presented a promising inhibition of
melanoma tumor growth in vivo and in vitro.
Biography
Hsin-Yu Chou, a fresh year PhD at Graduate Institute of Biomedical Engineering (National Chung Hsing University), graduated from the Department of Graduate
Institute of Medicine, College of Medicine, Kaohsiung Medical University, Taiwan. His research area focused on phototoxic injury and skin cancer research.